'Poorly Drafted' Patent Deals Can't End Janssen Suit: Judge

By Jeff Overley (October 31, 2017, 9:36 PM EDT) -- A Massachusetts federal judge on Tuesday refused to toss Janssen Biotech Inc.'s patent suit targeting Pfizer Inc.'s biosimilar of blockbuster biologic Remicade, despite finding that assignments of patent rights to Janssen were ambiguous and "poorly drafted."...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!